Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first... | May 1, 2023

Related Keywords

Xencor Xmab ,Xencor Inc ,Nasdaq , ,Xencor ,Nc Stock Exchange ,News ,Information ,Press Release ,Iopharmaceutical ,Company ,Developing ,Engineered ,Antibodies ,End ,Ytokines ,Or ,The ,Treatment ,F ,Dancer ,Autoimmune ,Oday ,Nnounced ,It ,Hill ,Elease Xncr Us98401f1057 ,